Lilly shuffles business structure; Novartis writes off part of Avidity deal

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 28 Oct, 13:27 UTC

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.

science

Sources

• T2Lilly shuffles business structure; Novartis writes off part of Avidity dealBioPharma Dive / Healthcare Dive / MedTech Dive28 Oct, 13:27